Ayse Akcan Arikan, MD, FAAP, FASN

Dr. Ayse Akcan Arikan is a dual-trained pediatric intensivist and nephrologist and an Associate Professor of Pediatrics with tenure at Baylor College of Medicine. She holds joint appointments in Pediatric Critical Care Medicine and Pediatric Renal Services. As a clinician-scientist, her research focuses on acute kidney injury in critically ill children, pharmacokinetics during extracorporeal therapies, management of multiple organ failure, and improving sepsis resuscitation outcomes.
Dr. Akcan Arikan earned her medical degree at Istanbul University Cerrahpasa Faculty of Medicine and completed dual fellowships in Pediatric Critical Care Medicine and Pediatric Nephrology at Baylor College of Medicine/Texas Children’s Hospital. She is the Medical Director of the Critical Care Nephrology and Acute Dialysis Program and the Medical Director of the Extracorporeal Liver Support Program at Texas Children’s Hospital.
Under her leadership, the Critical Care Nephrology Program established the first postdoctoral advanced training fellowship in pediatric critical care nephrology in North America. The program also features an innovative quality assurance and improvement initiative focused on patient safety in acute renal extracorporeal therapies through active surveillance.
Dr. Akcan Arikan is a principal investigator in multiple NIH-funded studies and has contributed extensively to research in her field with over 100 peer-reviewed publications. She is actively involved in mentoring the next generation of clinicians and scientists and collaborates with national and international research networks to advance critical care nephrology and improve pediatric outcomes.
Financial relationships
-
Attribution:SelfType of financial relationship:OtherIneligible company:SeastarTopic:Scientific Advisory BoardDate added:12/06/2024Date updated:12/06/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:MallinckrodtTopic:Scientific Advisory BoardDate added:12/06/2024Date updated:12/06/2024
-
Type of financial relationship:OtherIneligible company:CSLViforTopic:Scientific Advisory BoardDate added:12/06/2024Date updated:12/06/2024Relationship end date:12/01/2024